跳至主要内容
临床试验/NCT02550964
NCT02550964Unknown不适用

Incidence and Risk Factor Evaluation for Toxic Maculopathy Associated With Hydroxychloroquine and Chloroquine

Asan Medical Center1 个研究点 分布在 1 个国家目标入组 124 人开始时间: 2014年1月最近更新:
适应症

试验速览

阶段
不适用
入组人数
124
试验地点
1
主要终点
Incidence of toxic maculopathy associated with HCQ or CQ

研究概览

简要总结

The purpose of this study is to evaluate the incidence and risk factor of toxic maculopathy who treated with hydroxychloroquine or chloroquine due to their autoimmune disease such as rheumatoid arthritis or systemic lupus erythematosus. Total 5-year of the study periods, the investigators will screen these patients by baseline examination (Fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography) and observe with same examination for every year.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient who treated with HCQ or CQ due to autoimmune diseases such as RA, SLE
  • Patient who did not previously diagnosed with HCQ/CQ toxic retinopathy

排除标准

  • Aged less than 19 years

结局指标

主要结局

Incidence of toxic maculopathy associated with HCQ or CQ

时间窗: 1 years

次要结局

  • Characteristics and type of HCQ/CQ retinopathy (parafoveal or pericentral retinopathy)(5 years)
  • Progression of retinopathy after drug cessation(1 years)
  • Risk factor of HCQ/CQ retinopathy(5 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

JooYong Lee

Associate Professor

Asan Medical Center

研究点 (1)

Loading locations...

相似试验